| RCL |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$4.10 vs. cons $3.95 |
MEDIUM |
| RCL |
Report |
Revenue (Q2'26) |
IN-LINE |
pred ~$4.85B vs. cons $4.82B |
MEDIUM |
| RCL |
Report |
Net Yield, const. ccy (Q2'26) |
BEAT |
pred ~+1.5% vs. cons/guide ~+0.2% |
MEDIUM |
| RCL |
Guide |
FY2026 Adjusted EPS guide |
UNCHANGED |
guide ~$17.20-17.60 vs. cons $17.40 (FY26); midpoint reaffirmed with fuel offsetting Med recovery |
MEDIUM |
| RCL |
Guide |
Q3'26 Adjusted EPS guide |
LOWER |
guide ~$5.55-5.70 vs. cons $5.75 (Q3'26); ~200bps Europe yield drag + fuel |
MEDIUM |
| RCL |
Guide |
FY2026 Net Yield, const. ccy |
UNCHANGED |
guide ~+1.5-2.5% vs. cons ~+2.0% (FY26); 2H 'smiley-face' relies on Q4 accel |
MEDIUM |
| RCL |
Guide |
FY2026 NCC ex-fuel, const. ccy |
BETTER |
guide ~flat-to-slightly-below vs. cons ~+0.5% (FY26); continued cost beat |
MEDIUM |
| RCL |
Guide |
Forward booking / 2027 Med commentary |
BETTER |
qualitatively better: record book position, 2027 Europe clean vs. cautious cons (FY27 setup) |
LOW |
| RCL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| RCL |
Return |
5-day cumulative residual |
+1.0% (FADE) |
Q2 beats on EPS/yield/costs and FY midpoint is reaffirmed, driving an initial pop — but the stock rallied ~7% into the print, so expectations are rebuilt. Out-period math is the drag: the depressed Q3 guide (Europe ~200bps yield hit + elevated fuel) and reliance on a Q4 yield 'smiley-face' cap near-term estimate revisions, so early gains partially fade even after a headline beat. |
MEDIUM |